Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

NCT04536922 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Subject no longer able to participate in this single pt study.

Conditions

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Aldesleukin
DRUG: Pembrolizumab (KEYTRUDA(R))
BIOLOGICAL: Individual Patient TCR-Transduced PBL

Sponsor

National Cancer Institute (NCI)